GSK signed a 12-asset licensing deal with Hengrui Pharma. Generic erosion on Vyvanse continued to hurt Takeda. Celltrion is ...

Out-licensing drugs to multinational corporations is a natural step for Chinese biotechs, but the recent rise in deals is ...

With a portfolio of 14 potential blockbuster treatments that it expects to launch over the next five years, GSK is sticking ...

Symphony Limited announced its financial results for the quarter ending June 2025, reporting a 36% year-on-year decline in ...

The U.S. dollar remained under pressure as expectations build for a potential Federal Reserve rate cut in September.

These 10 stocks could mint the next wave of millionaires › IDEAYA Biosciences (NASDAQ:IDYA), a precision oncology company focused on developing targeted therapies for cancer, reported its ...

GSK gained after saying it expects to be towards the top end of its financial guidance for 2025 as it posted a 6% jump in ...

BAE Systems also came under pressure, falling 24p to 1797p despite its upgrade to 2025 guidance. GSK also surrendered initial ...

China's factory output shrank more than expected in July, official data showed on Thursday, logging its fourth straight month ...

The pharmaceutical industry has long protested the idea of globally linked drug prices as a threat to years of U.S. dominance ...

Trump gave the companies 60 days to voluntarily comply, threatening to "deploy every tool in our arsenal to protect American ...